Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534511 | 0.75 | LMNA (0.62) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL28955974 | 0.73 | ATAD2 (0.47) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL1165152 | 0.72 | LMNA (0.48) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL27863164 | 0.69 | LMNA (0.54) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL18640387 | 0.69 | KMT2A (0.44) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL2532353 | 0.68 | LMNA (0.53) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL2532356 | 0.68 | LMNA (0.53) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL2532358 | 0.68 | LMNA (0.53) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL14921881 | 0.67 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL31258082 | 0.66 | ALDH1A1 (0.62) | ALDH1A1CYP1A2LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058289-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1786812-B1 | PYRIDINE METHYLENE AZOLIDINONES AND THEIR USE AS PHOSPHOINOSITIDE INHIBITORS | MERCK SERONO SA (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20110034458-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034458-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | PIK3CD, PIK3CA, PTEN | ALDH1A1 1232/4885CYP1A2 2335/4885LMNA 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.